Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E.

Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019.

2.

TLR3 Activation of Intratumoral CD103+ Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity.

Roselli E, Araya P, Núñez NG, Gatti G, Graziano F, Sedlik C, Benaroch P, Piaggio E, Maccioni M.

Front Immunol. 2019 Mar 20;10:503. doi: 10.3389/fimmu.2019.00503. eCollection 2019.

3.

IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.

Caudana P, Núñez NG, De La Rochere P, Pinto A, Denizeau J, Alonso R, Niborski LL, Lantz O, Sedlik C, Piaggio E.

Cancer Immunol Res. 2019 Mar;7(3):443-457. doi: 10.1158/2326-6066.CIR-18-0697. Epub 2019 Jan 16.

PMID:
30651291
4.

CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes.

Frazao A, Messaoudene M, Nunez N, Dulphy N, Roussin F, Sedlik C, Zitvogel L, Piaggio E, Toubert A, Caignard A.

Cancer Immunol Res. 2019 Feb;7(2):208-218. doi: 10.1158/2326-6066.CIR-18-0085. Epub 2018 Dec 4.

PMID:
30514793
5.

Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node.

Alonso R, Flament H, Lemoine S, Sedlik C, Bottasso E, Péguillet I, Prémel V, Denizeau J, Salou M, Darbois A, Núñez NG, Salomon B, Gross D, Piaggio E, Lantz O.

Nat Commun. 2018 May 29;9(1):2113. doi: 10.1038/s41467-018-04524-x.

6.

CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells.

Canale FP, Ramello MC, Núñez N, Araujo Furlan CL, Bossio SN, Gorosito Serrán M, Tosello Boari J, Del Castillo A, Ledesma M, Sedlik C, Piaggio E, Gruppi A, Acosta Rodríguez EA, Montes CL.

Cancer Res. 2018 Jan 1;78(1):115-128. doi: 10.1158/0008-5472.CAN-16-2684. Epub 2017 Oct 24.

7.

Loss of immune tolerance to IL-2 in type 1 diabetes.

Pérol L, Lindner JM, Caudana P, Nunez NG, Baeyens A, Valle A, Sedlik C, Loirat D, Boyer O, Créange A, Cohen JL, Rogner UC, Yamanouchi J, Marchant M, Leber XC, Scharenberg M, Gagnerault MC, Mallone R, Battaglia M, Santamaria P, Hartemann A, Traggiai E, Piaggio E.

Nat Commun. 2016 Oct 6;7:13027. doi: 10.1038/ncomms13027.

8.

Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.

Sedlik C, Heitzmann A, Viel S, Ait Sarkouh R, Batisse C, Schmidt F, De La Rochere P, Amzallag N, Osinaga E, Oppezzo P, Pritsch O, Sastre-Garau X, Hubert P, Amigorena S, Piaggio E.

Oncoimmunology. 2016 Apr 22;5(7):e1171434. doi: 10.1080/2162402X.2016.1171434. eCollection 2016 Jul.

9.

Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response.

Knittel D, Gadzinski A, Hua S, Denizeau J, Savatier A, de la Rochère P, Boulain JC, Amigorena S, Piaggio E, Sedlik C, Léonetti M.

Vaccine. 2016 Jun 8;34(27):3093-3101. doi: 10.1016/j.vaccine.2016.04.073. Epub 2016 May 4.

PMID:
27154391
10.

The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.

Laubreton D, Bay S, Sedlik C, Artaud C, Ganneau C, Dériaud E, Viel S, Puaux AL, Amigorena S, Gérard C, Lo-Man R, Leclerc C.

Cancer Immunol Immunother. 2016 Mar;65(3):315-25. doi: 10.1007/s00262-016-1802-0. Epub 2016 Feb 4.

11.

Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms.

Sedlik C, Vigneron J, Torrieri-Dramard L, Pitoiset F, Denizeau J, Chesneau C, de la Rochere P, Lantz O, Thery C, Bellier B.

J Extracell Vesicles. 2014 Aug 27;3. doi: 10.3402/jev.v3.24646. eCollection 2014.

12.

Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.

Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotévi O.

Clin Cancer Res. 2012 Nov 15;18(22):6284-95. doi: 10.1158/1078-0432.CCR-12-0896. Epub 2012 Oct 2.

13.

Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine storm.

Kitamura H, Sedlik C, Jacquet A, Zaragoza B, Dusseaux M, Premel V, Sastre-Garau X, Lantz O.

J Immunol. 2010 Jul 15;185(2):892-901. doi: 10.4049/jimmunol.1000933. Epub 2010 Jun 11.

14.

Long-lasting cross-presentation of tumor antigen in human DC.

Faure F, Mantegazza A, Sadaka C, Sedlik C, Jotereau F, Amigorena S.

Eur J Immunol. 2009 Feb;39(2):380-90. doi: 10.1002/eji.200838669.

15.

Acidosis improves uptake of antigens and MHC class I-restricted presentation by dendritic cells.

Vermeulen M, Giordano M, Trevani AS, Sedlik C, Gamberale R, Fernández-Calotti P, Salamone G, Raiden S, Sanjurjo J, Geffner JR.

J Immunol. 2004 Mar 1;172(5):3196-204.

16.

In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway.

Morón VG, Rueda P, Sedlik C, Leclerc C.

J Immunol. 2003 Sep 1;171(5):2242-50.

17.

A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation.

Sedlik C, Orbach D, Veron P, Schweighoffer E, Colucci F, Gamberale R, Ioan-Facsinay A, Verbeek S, Ricciardi-Castagnoli P, Bonnerot C, Tybulewicz VL, Di Santo J, Amigorena S.

J Immunol. 2003 Jan 15;170(2):846-52.

18.

FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection.

Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, van Lent PL, Hofhuis FM, van Ojik HH, Sedlik C, da Silveira SA, Gerber J, de Jong YF, Roozendaal R, Aarden LA, van den Berg WB, Saito T, Mosser D, Amigorena S, Izui S, van Ommen GJ, van Vugt M, van de Winkel JG, Verbeek JS.

Immunity. 2002 Mar;16(3):391-402.

19.

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo.

Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJ, Verbeek JS, Ossendorp F.

J Immunol. 2002 Mar 1;168(5):2240-6.

20.

Vesicular stomatitis virus and pseudorabies virus induce a vig1/cig5 homologue in mouse dendritic cells via different pathways.

Boudinot P, Riffault S, Salhi S, Carrat C, Sedlik C, Mahmoudi N, Charley B, Benmansour A.

J Gen Virol. 2000 Nov;81(Pt 11):2675-82.

PMID:
11038379
21.

In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Sedlik C, Dadaglio G, Saron MF, Deriaud E, Rojas M, Casal SI, Leclerc C.

J Virol. 2000 Jul;74(13):5769-75.

22.

Immune responses induced by recombinant BCG strains according to level of production of a foreign antigen: malE.

Himmelrich H, Lo-Man R, Winter N, Guermonprez P, Sedlik C, Rojas M, Monnaie D, Gheorghiu M, Lagranderie M, Hofnung M, Gicquel B, Clément JM, Leclerc C.

Vaccine. 2000 Jun 1;18(24):2636-47.

PMID:
10781849
23.

mAb against hen egg-white lysozyme regulate its presentation to CD4(+) T cells.

Guermonprez P, Lo-Man R, Sedlik C, Rojas MJ, Poljak RJ, Leclerc C.

Int Immunol. 1999 Nov;11(11):1863-72.

PMID:
10545490
24.

Engineering parvovirus-like particles for the induction of B-cell, CD4(+) and CTL responses.

Rueda P, Martínez-Torrecuadrada JL, Sarraseca J, Sedlik C, del Barrio M, Hurtado A, Leclerc C, Casal JI.

Vaccine. 1999 Sep;18(3-4):325-32.

PMID:
10506659
25.

HLA-G inhibits the allogeneic proliferative response.

Riteau B, Menier C, Khalil-Daher I, Sedlik C, Dausset J, Rouas-Freiss N, Carosella ED.

J Reprod Immunol. 1999 Jul;43(2):203-11.

PMID:
10479056
26.

Role of HLA-G versus HLA-E on NK function: HLA-G is able to inhibit NK cytolysis by itself.

Khalil-Daher I, Riteau B, Menier C, Sedlik C, Paul P, Dausset J, Carosella ED, Rouas-Freiss N.

J Reprod Immunol. 1999 Jul;43(2):175-82.

PMID:
10479053
27.

HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes.

Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED, Rouas-Freiss N.

Int Immunol. 1999 Aug;11(8):1351-6.

PMID:
10421792
28.

Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses.

Sedlik C, Dridi A, Deriaud E, Saron MF, Rueda P, Sarraseca J, Casal JI, Leclerc C.

J Virol. 1999 Apr;73(4):2739-44.

29.
30.
31.
32.
33.

Antigens linked to synthetic microspheres induce immune responses in primates in the absence of adjuvant.

Sedlik C, Perraut R, Bonnemains B, Leclerc C.

Immunobiology. 1996 Jan;195(1):105-18.

PMID:
8852604
34.

Stimulation of a memory B cell response does not require primed helper T cells.

Leclerc C, Sedlik C, Lo-Man R, Charlot B, Rojas M, Dériaud E.

Eur J Immunol. 1995 Sep;25(9):2533-8.

PMID:
7589122
35.

Immunogenicity of poliovirus B and T cell epitopes presented by hybrid porcine parvovirus particles.

Sedlik C, Sarraseca J, Rueda P, Leclerc C, Casal I.

J Gen Virol. 1995 Sep;76 ( Pt 9):2361-8.

PMID:
7561778

Supplemental Content

Loading ...
Support Center